| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
IN 1130 manufacturers
- IN-1130
-
- $48.00
-
2026-08-30
- CAS:868612-83-3
- Purity: 99.79%
- Supply Ability: 10g
|
| | IN 1130 Basic information |
| Product Name: | IN 1130 | | Synonyms: | IN 1130;3-[[5-(6-Methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide;IN1130,IN 1130;Benzamide, 3-[[5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]-;3-((5-(6-Methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide;IN-1130, 10 mM in DMSO | | CAS: | 868612-83-3 | | MF: | C25H20N6O | | MW: | 420.47 | | EINECS: | | | Product Categories: | | | Mol File: | 868612-83-3.mol |  |
| | IN 1130 Chemical Properties |
| Boiling point | 705.6±60.0 °C(Predicted) | | density | 1.315±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 9.60±0.10(Predicted) | | form | Solid | | color | White to light yellow | | InChI | 1S/C25H20N6O/c1-15-4-2-7-20(29-15)24-23(17-8-9-19-21(14-17)28-11-10-27-19)30-22(31-24)13-16-5-3-6-18(12-16)25(26)32/h2-12,14H,13H2,1H3,(H2,26,32)(H,30,31) | | InChIKey | RYKSGWSKILPDDY-UHFFFAOYSA-N | | SMILES | [nH]1c(nc(c1c4cc5nccnc5cc4)c3nc(ccc3)C)Cc2cc(ccc2)C(=O)N |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | IN 1130 Usage And Synthesis |
| Uses | IN 1130 is a novel transforming growth factor-β type I receptor kinase (ALK5) inhibtior. In one study, it showed that IN-1130 was effective in prevention and treatment of renal fibrosis in rat unilateral ureteral obstruction model. | | Biological Activity | IN-1130 is a potent inhibitor of the activin receptor-like kinase ALK-5 (Type 1 TGF1β recptor). The compound inhibits phosphorylation of Smad-2 with an IC50 of 36 nM. IN-1130 inhibits renal fibrosis, and also reduces tumor volume in prostate tumor xenografts in murine models. | | in vivo | IN-1130 (10, 20 mg/kg/day; IP; for 7 and 14 days) reduces the extent of interstitial nephritis and fibrosis (arrowheads) with 10 mg/kg and significantly reduces or absent histopathological changes with 20 mg/kg in unilateral ureteral obstruction (UUO) rats[1].
IN-1130 (10, 20 mg/kg/day; for 14 days) dose-dependently decreases levels of TGF-β1 mRNA and suppresses phosphorylation of Smad2, α-SMA, myofibroblasts in rat UUO kidneys[1].
IN-1130 (40 mg/kg; IP; 3 times per week for 3 weeks) inhibits in vivo breast cancer metastasis to the lungs in MMTV/c-Neu mice (Eight-week-old female BALB/c mice)[2].
| Animal Model: | Six-week-old male Sprague–Dawley rats weighing 180-200 g[1] | | Dosage: | 10 and 20 mg/kg | | Administration: | IP; daily; for 7 and 14 days | | Result: | Reduced the extent of interstitial nephritis and fibrosis (arrowheads) with 10 mg/kg.
|
| | IC 50 | ALK5 | | storage | Store at +4°C |
| | IN 1130 Preparation Products And Raw materials |
|